Cell | CBD | TMZ | BCNU | CDDP | |||
---|---|---|---|---|---|---|---|
IC50 Value | FIC Index | IC50 Value | FIC Index | IC50 Value | FIC Index | ||
Human cell lines | |||||||
T98G | 1.00E-06 | 9.19E-04 ± 7.50E-05 | 0.76 ± 0.05 | 2.81E-04 ± 8.78E-05 | 1.10 ± 0.30 | 4.34E-05 ± 1.84E-05 | 5.73 ± 2.36 |
3.00E-06 | 6.83E-04 ± 1.55E-04 | 0.90 ± 0.10 | 1.94E-04 ± 1.08E-04 | 1.09 ± 0.37 | 3.92E-05 ± 2.12E-05 | 5.48 ± 2.73 | |
U251 | 1.00E-06 | 7.78E-04 ± 8.00E-05 | 1.86 ± 0.18 | 1.66E-04 ± 4.25E-05 | 1.26 ± 0.29 | 4.42E-05 ± 2.22E-05 | 4.24 ± 2.08 |
3.00E-06 | 8.99E-04 ± 8.54E-07 | 2.34 ± 0.00 | 2.40E-04 ± 2.75E-05 | 1.99 ± 0.19 | 5.99E-05 ± 7.51E-06 | 5.93 ± 0.70 | |
U87MG | 1.00E-06 | 9.17E-04 ± 1.79E-04 | 1.16 ± 0.19 | 5.86E-04 ± 8.58E-05 | 1.34 ± 0.17 | 2.48E-04 ± 5.15E-05 | 3.76 ± 0.74 |
3.00E-06 | 1.52E-03 ± 1.16E-03 | 2.19 ± 1.22 | 5.01E-04 ± 1.46E-04 | 1.57 ± 0.29 | 1.75E-04 ± 9.19E-06 | 3.11 ± 0.13 | |
Mouse primary cells | |||||||
PDGF-GBM | 1.00E-06 | 5.43E-04 ± 9.26E-05 | 10.78 ± 1.80* | 1.78E-05 ± 7.04E-07 | 2.14 ± 0.07 | 2.05E-06 ± 3.97E-07 | 2.72 ± 0.48 |
3.00E-06 | 1.20E-04 ± 6.86E-05 | 3.06 ± 1.33 | 1.47E-05 ± 4.44E-06 | 2.29 ± 0.47 | 3.14E-06 ± 5.68E-07 | 4.53 ± 0.69 | |
NPCs | 1.00E-06 | 1.24E-04 ± 4.55E-05 | 3.07 ± 1.01 | 3.29E-05 ± 1.81E-05 | 3.58 ± 1.79 | 8.32E-07 ± 1.56E-07 | 1.72 ± 0.26 |
3.00E-06 | 4.99E-05 ± 4.84E-05 | 2.05 ± 1.08 | 8.71E-06 ± 4.49E-06 | 1.80 ± 0.45 | 6.00E-07 ± 2.74E-07 | 1.95 ± 0.46 |
When DNA-damaging agents were combined with CBD at fixed concentration of 1 or 3 µM, IC50 values of the DNA-damaging agents and the efficacy FIC indices were calculated from the combinations producing half maximal inhibitory effects on inhibiting cell viability of human GBM cell lines, primary mouse PDGF-GBM cells, and NPCs. Synergy was defined as ΣFIC < 0.5, additivity was defined as 0.5 < ΣFIC < 4, and antagonism was defined as ΣFIC > 4. Vehicle comprised 0.05% dimethylsulfoxide (vehicle in lieu of CBD) plus 0.05% dimethylsulfoxide, ethanol, or PBS (vehicle in lieu of TMZ, BCNU, or CDDP, respectively).
* P < 0.05, mouse PDGF-GBM cells versus mouse NPCs.